Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene

Tohoku Journal of Experimental Medicine

Volumn 214, Issue 4, 2008, Pages 359-363

  Fukuhara, Tatsuro ^a   Saijo, Yasuo ^b   Sakakibara, Tomohiro ^a   Inoue, Akira ^a   Morikawa, Naoto ^a   Kanamori, Masayuki ^c   Nakashima, Ichiro ^c   Nukiwa, Toshihiro ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinomatous meningitis; EGF; EGF TKI; Gefitinib; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GADOLINIUM; GEFITINIB; LOCKED NUCLEIC ACID; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; BINDING AFFINITY; BRAIN RADIATION; CANCER REGRESSION; CANCER STAGING; CARCINOMATOUS MENINGITIS; CASE REPORT; CEREBROSPINAL FLUID CYTOLOGY; CEREBROSPINAL FLUID DRAINAGE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CODON; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; EXON; GENE DELETION; GENE MUTATION; HEADACHE; HUMAN; INTRACRANIAL HYPERTENSION; JAPANESE; LUMBAR PUNCTURE; LUNG ADENOCARCINOMA; LUNG DISEASE; MALE; MENINGEAL METASTASIS; NAUSEA; NECK PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; PAPILLEDEMA; POLYMERASE CHAIN REACTION; TEMPORAL LOBE; THORAX RADIOGRAPHY; TREATMENT RESPONSE; UNCONSCIOUSNESS; VISUAL IMPAIRMENT; ADENOCARCINOMA; GENETICS; LUNG TUMOR; MENINGIOMA; MENINGITIS; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; RADIOTHERAPY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL NEOPLASMS; MENINGITIS; MIDDLE AGED; MUTATION; QUINAZOLINES; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 44449131799     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.214.359     Document Type: Article

References (10)

1. Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., Watanabe, H., Saijo, Y. & Nukiwa, T. (2006) Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol., 24, 3340-3346.
2. Jackman, D.M., Holmes, A.J., Lindeman, N., Wen, P.Y., Kesari, S., Borras, A.M., Bailey, C., de Jong, F., Jänne, P.A. & Johnson, B.E. (2006) Response and resistance in a non-small cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J. Clin. Oncol., 24, 4517-4520.
3. Jones, H.K., Stafford, L.E., Swaisland, H.C. & Payne, R. (2002) A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials. J. Pharm. Biomed. Anal., 29, 221-228.
4. Kim, M.K., Lee, K.H., Lee, J.K., Choi, J.H. & Hyun, M.S. (2005) Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer, 50, 265-269.
5. McKillop, D., Hutchison, M., Partridge, E.A., Bushby, N., Cooper, C.M., Clarkson-Jones, J.A., Herron, W. & Swaisland, H.C. (2004) Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica, 34, 917-934.
6. Mukohara, T., Engelman, J.A., Hanna, N.H., Yeap, B.Y., Kobayashi, S., Lindeman, N., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L.C., Tenen, D.G., Johnson, B.E. & Jänne, P.A. (2005) Differential effects of gefitinib and cetuximab on non-small cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst., 97, 1185-1194.
7. Nagai, Y., Miyazawa, H., Huqun, T., Tanaka, T., Udagawa, K., Kato, M., Fukuyama, S., Yokote, A., Kobayashi, K., Kanazawa, M. & Hagiwara, K. (2005) Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res., 65, 7276-7282.
8. Namba, Y., Kijima, T., Yokota, S., Niinaka, M., Kawamura, S., Iwasaki, T., Takeda, Y., Kimura, H., Okada, T., Yamaguchi, T., Nakagawa, M., Okumura, Y., Maeda, H. & Ito, M. (2004) Gefitinib in patients with brain metastases from non-small cell lung cancer: review of 15 clinical cases. Clin. Lung Cancer, 6, 123-128.
9. Sakai, M., Ishikawa, S., Ito, H., Ozawa, Y., Yamamoto, T., Yamamoto, T., Onizuka, M. & Sakakibara, Y. (2006) Carcinomatous meningitis from non-small cell lung cancer responding to gefitinib. Int. J. Clin. Oncol., 11, 243-245.
10. Wu, C., Li, Y.L., Wang, Z.M., Li, Z., Zhang, T.X. & Wei, Z. (2007) Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer, 57, 359-364.